WP
Woodline Partners Portfolio holdings
AUM
$18.9B
1-Year Return
23.37%
This Quarter Return
+21.33%
1 Year Return
+23.37%
3 Year Return
+125.78%
5 Year Return
+185.63%
10 Year Return
–
AUM
$3.77B
AUM Growth
+$720M
(+24%)
Cap. Flow
+$382M
Cap. Flow
% of AUM
10.12%
Top 10 Holdings %
Top 10 Hldgs %
22.38%
Holding
294
New
116
Increased
45
Reduced
52
Closed
77
Top Buys
| 1 |
Amgen
AMGN
|
$115M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
$97.8M |
| 3 |
NXP Semiconductors
NXPI
|
$61.6M |
| 4 |
Eli Lilly
LLY
|
$57.7M |
| 5 |
Qorvo
QRVO
|
$53.9M |
Top Sells
| 1 |
Microchip Technology
MCHP
|
$72.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
$66.5M |
| 3 |
Amazon
AMZN
|
$65.6M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$57.9M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$53.4M |
Sector Composition
| 1 | Healthcare | 42.9% |
| 2 | Technology | 32.83% |
| 3 | Communication Services | 8.98% |
| 4 | Financials | 3.92% |
| 5 | Consumer Discretionary | 3.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Jabil
JBL
$22.5B
| $8.57M | 0.23% |
+201,415
| New | +$8.57M |
|
127
Zai Lab
ZLAB
$3.42B
| $8.31M | 0.22% |
+61,370
| New | +$8.31M |
|
|
BOWX
128
DELISTED
BowX Acquisition Corp. Class A Common Stock
BOWX
| $8.26M | 0.22% |
+805,161
| New | +$8.26M |
|
129
Outset Medical
OM
$249M
| $8.22M | 0.22% |
9,641
+1,269
| +15% | +$1.08M |
|
130
TripAdvisor
TRIP
$2.05B
| $8.06M | 0.21% |
280,000
-1,221,295
| -81% | -$35.1M |
|
131
Chewy
CHWY
$17.5B
| $7.81M | 0.21% |
+86,843
| New | +$7.81M |
|
132
Monster Beverage
MNST
$61B
| $7.45M | 0.2% |
+161,036
| New | +$7.45M |
|
133
Semtech
SMTC
$5.26B
| $7.43M | 0.2% |
+103,084
| New | +$7.43M |
|
134
PTC Therapeutics
PTCT
$4.55B
| $7.35M | 0.2% |
120,471
-172,139
| -59% | -$10.5M |
|
135
Airbnb
ABNB
$75.8B
| $7.34M | 0.19% |
+50,000
| New | +$7.34M |
|
136
Under Armour
UAA
$2.2B
| $7.33M | 0.19% |
+426,684
| New | +$7.33M |
|
137
New York Times
NYT
$9.6B
| $7.27M | 0.19% |
+140,472
| New | +$7.27M |
|
138
Zentalis Pharmaceuticals
ZNTL
$126M
| $7.27M | 0.19% |
140,000
+2,116
| +2% | +$110K |
|
139
Forte Biosciences
FBRX
$140M
| $7M | 0.19% |
+7,691
| New | +$7M |
|
|
DISH
140
DELISTED
DISH Network Corp.
DISH
| $6.99M | 0.19% |
+216,003
| New | +$6.99M |
|
141
Akebia Therapeutics
AKBA
$785M
| $6.67M | 0.18% |
2,382,522
-3,076,414
| -56% | -$8.61M |
|
142
Scholar Rock
SRRK
$3.02B
| $6.62M | 0.18% |
+136,458
| New | +$6.62M |
|
|
KRON
143
DELISTED
Kronos Bio
KRON
| $6.62M | 0.18% |
+221,487
| New | +$6.62M |
|
|
JNCE
144
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $6.59M | 0.17% |
940,902
+11,251
| +1% | +$78.8K |
|
145
Charles River Laboratories
CRL
$8.07B
| $6.55M | 0.17% |
+26,203
| New | +$6.55M |
|
146
Viatris
VTRS
$12.2B
| $6.49M | 0.17% |
+346,228
| New | +$6.49M |
|
147
Cue Biopharma
CUE
$59.9M
| $6.38M | 0.17% |
510,088
-404,574
| -44% | -$5.06M |
|
148
WEX
WEX
$5.87B
| $6.27M | 0.17% |
+30,816
| New | +$6.27M |
|
149
Tango Therapeutics
TNGX
$772M
| $5.76M | 0.15% |
503,397
+3,397
| +0.7% | +$38.9K |
|
|
BLSA
150
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $5.71M | 0.15% |
+512,616
| New | +$5.71M |
|